Brinker Capital Inc. Has $707,000 Stake in Teleflex Incorporated (NYSE:TFX)

Brinker Capital Inc. lessened its position in shares of Teleflex Incorporated (NYSE:TFX) by 18.6% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 2,736 shares of the medical technology company’s stock after selling 626 shares during the quarter. Brinker Capital Inc.’s holdings in Teleflex were worth $707,000 at the end of the most recent quarter.

A number of other large investors have also recently added to or reduced their stakes in TFX. LPL Financial LLC bought a new position in shares of Teleflex in the 3rd quarter worth $234,000. First Citizens Bank & Trust Co. lifted its stake in Teleflex by 8.3% during the 4th quarter. First Citizens Bank & Trust Co. now owns 1,734 shares of the medical technology company’s stock valued at $448,000 after acquiring an additional 133 shares in the last quarter. State of Alaska Department of Revenue lifted its stake in Teleflex by 1.8% during the 4th quarter. State of Alaska Department of Revenue now owns 4,986 shares of the medical technology company’s stock valued at $1,287,000 after acquiring an additional 87 shares in the last quarter. Cohen & Steers Inc. lifted its stake in Teleflex by 79.6% during the 3rd quarter. Cohen & Steers Inc. now owns 61,707 shares of the medical technology company’s stock valued at $16,420,000 after acquiring an additional 27,342 shares in the last quarter. Finally, Korea Investment CORP bought a new position in Teleflex during the 4th quarter valued at $137,000. 91.82% of the stock is owned by institutional investors and hedge funds.

TFX stock traded down $2.39 during mid-day trading on Monday, reaching $302.74. 200,274 shares of the company traded hands, compared to its average volume of 441,528. The firm has a market capitalization of $14.06 billion, a PE ratio of 30.58, a PEG ratio of 2.05 and a beta of 1.07. The company has a quick ratio of 1.39, a current ratio of 2.12 and a debt-to-equity ratio of 0.82. Teleflex Incorporated has a 52-week low of $226.02 and a 52-week high of $309.99.

Teleflex (NYSE:TFX) last issued its quarterly earnings results on Thursday, February 21st. The medical technology company reported $2.77 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $2.76 by $0.01. The firm had revenue of $641.60 million during the quarter, compared to the consensus estimate of $641.06 million. Teleflex had a return on equity of 18.47% and a net margin of 8.20%. The company’s revenue for the quarter was up 7.8% on a year-over-year basis. During the same quarter last year, the company posted $2.44 EPS. On average, equities research analysts anticipate that Teleflex Incorporated will post 11.03 EPS for the current fiscal year.

In other Teleflex news, Director Benson Smith sold 8,500 shares of the business’s stock in a transaction that occurred on Wednesday, April 10th. The stock was sold at an average price of $305.83, for a total value of $2,599,555.00. Following the completion of the sale, the director now owns 84,913 shares in the company, valued at $25,968,942.79. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Cameron P. Hicks sold 2,000 shares of the business’s stock in a transaction that occurred on Wednesday, February 27th. The shares were sold at an average price of $288.00, for a total value of $576,000.00. Following the completion of the sale, the vice president now owns 4,696 shares of the company’s stock, valued at approximately $1,352,448. The disclosure for this sale can be found here. Insiders sold a total of 28,176 shares of company stock valued at $8,375,760 in the last 90 days. 2.36% of the stock is currently owned by corporate insiders.

Several equities analysts have weighed in on the company. Raymond James raised their price objective on Teleflex from $320.00 to $348.00 and gave the company a “strong-buy” rating in a research note on Wednesday, March 27th. Needham & Company LLC restated a “buy” rating and set a $325.00 price objective on shares of Teleflex in a research note on Tuesday, March 26th. Barclays lifted their target price on Teleflex from $287.00 to $309.00 and gave the stock an “equal weight” rating in a research note on Monday. Zacks Investment Research upgraded Teleflex from a “sell” rating to a “hold” rating in a research note on Tuesday, February 26th. Finally, UBS Group lifted their target price on Teleflex to $350.00 and gave the stock a “buy” rating in a research note on Friday, March 22nd. Three research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. Teleflex currently has a consensus rating of “Buy” and an average target price of $316.13.

ILLEGAL ACTIVITY NOTICE: This article was published by Baseball Daily News and is the property of of Baseball Daily News. If you are reading this article on another website, it was illegally stolen and republished in violation of international copyright and trademark laws. The legal version of this article can be read at https://www.baseballdailydigest.com/news/2019/04/15/brinker-capital-inc-has-707000-position-in-teleflex-incorporated-tfx.html.

Teleflex Profile

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It offers vascular access products that comprise Arrow branded catheters and related devices, including catheter positioning systems for use in the administration of intravenous medications and other therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site; and devices for treating coronary and peripheral vascular disease.

Recommended Story: Buy-Side Analysts

Institutional Ownership by Quarter for Teleflex (NYSE:TFX)

Receive News & Ratings for Teleflex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex and related companies with MarketBeat.com's FREE daily email newsletter.